Polio - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Polio - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Polio - Pipeline Review, H2 2014', provides an overview of the Polio's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polio
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polio
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polio Overview 8
Therapeutics Development 9
Pipeline Products for Polio - Overview 9
Pipeline Products for Polio - Comparative Analysis 10
Polio - Therapeutics under Development by Companies 11
Polio - Therapeutics under Investigation by Universities/Institutes 13
Polio - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Polio - Products under Development by Companies 18
Polio - Products under Investigation by Universities/Institutes 19
Polio - Companies Involved in Therapeutics Development 20
Sanofi 20
GlaxoSmithKline plc 21
Takeda Pharmaceutical Company Limited 22
Biological E. Limited 23
Panacea Biotec Limited 24
Sinovac Biotech Ltd. 25
Beijing Tiantan Biological Products Co., Ltd. 26
Sentinext Therapeutics Sdn Bhd 27
Sanofi Pasteur SA 28
Codagenix, Inc. 29
Polio - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
diphtheria + tetanus toxoids + acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis (inactivated) + haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GSK-217744 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TAK-361S - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
V-073 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Monovalent Inactivated Poliovirus Type 2 Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DTwP-IPV - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
poliomyelitis vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Monovalent Oral Vaccine for Polio - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IPVGVI-3000 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Polio Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Polio Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Polio Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DTwP-Hep B-IPV-Hib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Hep B-IPV-Hib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DTwP-IPV + Hib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
polio vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Polio - Recent Pipeline Updates 59
Polio - Dormant Projects 60
Polio - Product Development Milestones 61
Featured News & Press Releases 61
Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication 61
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 61
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 62
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 63
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 63
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 63
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 64
Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU 64
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Polio, H2 2014 9
Number of Products under Development for Polio - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Polio - Pipeline by Sanofi, H2 2014 20
Polio - Pipeline by GlaxoSmithKline plc, H2 2014 21
Polio - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 22
Polio - Pipeline by Biological E. Limited, H2 2014 23
Polio - Pipeline by Panacea Biotec Limited, H2 2014 24
Polio - Pipeline by Sinovac Biotech Ltd., H2 2014 25
Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 26
Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2014 27
Polio - Pipeline by Sanofi Pasteur SA, H2 2014 28
Polio - Pipeline by Codagenix, Inc., H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Assessment by Combination Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Polio Therapeutics - Recent Pipeline Updates, H2 2014 59
Polio - Dormant Projects, H2 2014 60